BioCentury
ARTICLE | Product Development

Autoimmune CAR Ts: Is CD19 enough?

Presentations from iCell, JW and others at EULAR provide new insight into autoimmune CAR T mechanisms

June 17, 2024 11:36 PM UTC

The promise of CAR T cell therapies for autoimmune diseases hangs largely on CD19-directed therapies, but research emerging from the EULAR Congress last week provides new insights into when CD19-targeting might not be enough, and the other mechanisms that may drive long-term remissions when it’s not. 

At the European Alliance of Associations for Rheumatology (EULAR) Congress, at least eight abstract presentations focused on CAR T cell therapies for rheumatic diseases. ...